Guiqi Baizhu prescription ameliorates cytarabine-induced intestinal mucositis by targeting JAK2 to inhibit M1 macrophage polarization

MLA

Wei Chu, et al. “Guiqi Baizhu Prescription Ameliorates Cytarabine-Induced Intestinal Mucositis by Targeting JAK2 to Inhibit M1 Macrophage Polarization.” Biomedicine & Pharmacotherapy, vol. 164, Aug. 2023, p. 114902. EBSCOhost, https://doi.org/10.1016/j.biopha.2023.114902.

APA

Wei Chu, Ya-ling Li, Jun-jie Li, Jia Lin, Mi Li, Jiao Wang, Jian-zheng He, Yue-mei Zhang, Juan Yao, Xiao-jie Jin, Hui Cai, & Yong-qi Liu. (2023). Guiqi Baizhu prescription ameliorates cytarabine-induced intestinal mucositis by targeting JAK2 to inhibit M1 macrophage polarization. Biomedicine & Pharmacotherapy, 164, 114902. https://doi.org/10.1016/j.biopha.2023.114902

Chicago

Wei Chu, Ya-ling Li, Jun-jie Li, Jia Lin, Mi Li, Jiao Wang, Jian-zheng He, et al. 2023. “Guiqi Baizhu Prescription Ameliorates Cytarabine-Induced Intestinal Mucositis by Targeting JAK2 to Inhibit M1 Macrophage Polarization.” Biomedicine & Pharmacotherapy 164 (August): 114902. doi:10.1016/j.biopha.2023.114902.